Health Condition 1: I222- Subsequent non-ST elevation (NSTEMI) myocardial infarction
Conditions
Interventions
Intervention1: beetroot juice: concentrated beetroot juice without diluting with water and without adding sugar
Control Intervention1: HYDRATION REGIMEN: Hydration therapy at 1-1.5ml/kg/hr for 3- 12ho
Sponsors
AMRITA SCHOOL OF PHARMACY
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patient undergoing coronary angiography or PCI for NSTE-ACS 2. Requirement for CIN prophylaxis as per Barts Heart Centre Criteria for CIN prophylaxis: - eGFR less than 60ml/min or - 2 of the following: diabetes, liver failure(cirrhosis), age more than 70 years, exposure to contrast in last 7 days, heart failure (LVEF less than 40%), concomitant renally active drugs (ACEI, ARB, NSAIDs, aminoglycosides, diuretics) 3. Age more than or equal to 18 4. Patients able and willing to give their written informed consent
Exclusion criteria
Exclusion criteria: 1. ST segment elevation myocardial infarction undergoing Primary PCI 2. Patients with eGFR less than 20 ml/min or on renal replacement therapy. 3. Subjects presenting with cardiogenic shock(systolic blood pressure less than 80mmHg for more than 30 min or requiring inotropes or emergency intra aortic balloon pump for hypotension treatment) or cardiopulmonary resuscitation. 4. Current life-threatening condition other than vascular disease that may prevent a subject completing the study. 5. Use of an investigational devise or investigational drug within 30days or 5 half-life (whichever is the longer) preceding the first dose of study medication. 6. Severe acute infection. 7. Pregnancy. This will be tested by urine HcG measurement. 8. Systemic autoimmune disease such as rheumatoid arthritis or other conditions known to be associated with chronic inflammation such as inflammatory bowel disease. 9. Patients who have donated more than 500ml of blood within 56 days prior to study medication administration. 10. A history of chronic viral hepatitis(including presence of hepatitis B surface antigen or Hepatitis C antibody or other chronic hepatic disorder) or HIV. 11. Patients unable to take oral feeds. 12. Any Inclusion Criterion not met.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of CINTimepoint: Feb 2025 to April 2025 | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse eventsTimepoint: 5-7 days | — |
Countries
India
Contacts
Public ContactSachin G Nair
AMRITA INSTITUTE OF MEDICAL SCIENCES AND RESEARCH CENTRE
Outcome results
None listed